Latest filing published 10 Sept 2026 for Iovance Biotherapeutics, INC.. Read the official filing
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Raj K. Puri discloses dealings in Iovance Biotherapeutics, Inc. to SEC (Form 4). Over a trading history stretching from 16 December 2024 to 8 September 2026, the count stands at 13 filings.
Every open-market trade on record is a purchase: 1 purchase worth €8,636, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 2 share grants and 10 option exercises.
The newest entry dates from 10 September 2026: an option exercise, in Iovance Biotherapeutics, Inc. The last insider purchase was made public on 27 May 2025, 509 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations